Researchers from the University of Delaware and the Delaware Biotechnology Institute in Newark have created new drug-delivery systems with the potential to improve treatment for diseases that affect connective tissues, such as osteoarthritis or rheumatoid arthritis. The researchers devised cargo-carrying nanoparticles and are working to program these nanoparticles to selectively bind to degrading collagen in the body. When collagen degrades, as a result of disease or injury, the nanoparticles attach and remain at the injury site longer than many current treatment options. This allows for the possibility of delivering site-specific medicines over longer periods of time – from days to weeks.
An official website of the United States government.